201 related articles for article (PubMed ID: 21952235)
21. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
22. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis.
Elabd C; Basillais A; Beaupied H; Breuil V; Wagner N; Scheideler M; Zaragosi LE; Massiéra F; Lemichez E; Trajanoski Z; Carle G; Euller-Ziegler L; Ailhaud G; Benhamou CL; Dani C; Amri EZ
Stem Cells; 2008 Sep; 26(9):2399-407. PubMed ID: 18583541
[TBL] [Abstract][Full Text] [Related]
23. Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats.
Yao Q; Ni J; Hou Y; Ding L; Zhang L; Jiang H
Cell Biochem Biophys; 2014 Jun; 69(2):229-35. PubMed ID: 24254971
[TBL] [Abstract][Full Text] [Related]
24. PPARγ forms a bridge between DNA methylation and histone acetylation at the C/EBPα gene promoter to regulate the balance between osteogenesis and adipogenesis of bone marrow stromal cells.
Zhao QH; Wang SG; Liu SX; Li JP; Zhang YX; Sun ZY; Fan QM; Tian JW
FEBS J; 2013 Nov; 280(22):5801-14. PubMed ID: 23981481
[TBL] [Abstract][Full Text] [Related]
25. Caffeine regulates osteogenic differentiation and mineralization of primary adipose-derived stem cells and a bone marrow stromal cell line.
Su SJ; Chang KL; Su SH; Yeh YT; Shyu HW; Chen KM
Int J Food Sci Nutr; 2013 Jun; 64(4):429-36. PubMed ID: 23301724
[TBL] [Abstract][Full Text] [Related]
26. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
[TBL] [Abstract][Full Text] [Related]
27. [Research progression of deacetylase (SIRT1)].
Chen HZ; Zhang ZQ; Wei YS; Liu DP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Jun; 29(3):441-7. PubMed ID: 17633479
[TBL] [Abstract][Full Text] [Related]
28. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
29. Sirt1 Promotes a Thermogenic Gene Program in Bone Marrow Adipocytes: From Mice to (Wo)Men.
Artsi H; Gurt I; El-Haj M; Müller R; Kuhn GA; Ben Shalom G; Cohen-Kfir E; Abramowitz E; Kandel L; Safran O; Dresner-Pollak R
Front Endocrinol (Lausanne); 2019; 10():126. PubMed ID: 30873124
[TBL] [Abstract][Full Text] [Related]
30. SIRT1 haplo-insufficiency results in reduced cortical bone thickness, increased porosity and decreased estrogen receptor alpha in bone in adult 129/Sv female mice.
Artsi H; Cohen-Kfir E; Shahar R; Kalish-Achrai N; Lishinsky N; Dresner-Pollak R
Front Endocrinol (Lausanne); 2022; 13():1032262. PubMed ID: 36568088
[TBL] [Abstract][Full Text] [Related]
31.
Albiol L; Cilla M; Pflanz D; Kramer I; Kneissel M; Duda GN; Willie BM; Checa S
J R Soc Interface; 2018 Apr; 15(141):. PubMed ID: 29669893
[TBL] [Abstract][Full Text] [Related]
32. Comparative study of osteogenic differentiation potential of mesenchymal stem cells derived from bone marrow and adipose tissue of osteoporotic female rats.
Boeloni JN; Ocarino NM; Goes AM; Serakides R
Connect Tissue Res; 2014 Apr; 55(2):103-14. PubMed ID: 24175668
[TBL] [Abstract][Full Text] [Related]
33. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.
Rossini M; Gatti D; Adami S
Calcif Tissue Int; 2013 Aug; 93(2):121-32. PubMed ID: 23748710
[TBL] [Abstract][Full Text] [Related]
34. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.
Sutherland MK; Geoghegan JC; Yu C; Turcott E; Skonier JE; Winkler DG; Latham JA
Bone; 2004 Oct; 35(4):828-35. PubMed ID: 15454089
[TBL] [Abstract][Full Text] [Related]
35. Zinc finger protein 467 regulates Wnt signaling by modulating the expression of sclerostin in adipose derived stem cells.
You L; Chen L; Pan L; Gu WS; Chen JY
Biochem Biophys Res Commun; 2015 Jan; 456(2):598-604. PubMed ID: 25490389
[TBL] [Abstract][Full Text] [Related]
36. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
[TBL] [Abstract][Full Text] [Related]
37. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
[TBL] [Abstract][Full Text] [Related]
38. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
[TBL] [Abstract][Full Text] [Related]
39. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro.
Jäger A; Götz W; Lossdörfer S; Rath-Deschner B
J Periodontal Res; 2010 Apr; 45(2):246-54. PubMed ID: 19778325
[TBL] [Abstract][Full Text] [Related]
40. Combining sclerostin neutralization with tissue engineering: An improved strategy for craniofacial bone repair.
Maillard S; Sicard L; Andrique C; Torrens C; Lesieur J; Baroukh B; Coradin T; Poliard A; Slimani L; Chaussain C
Acta Biomater; 2022 Mar; 140():178-189. PubMed ID: 34875361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
